Spironolactone Medicaid Coverage by State: How to Get It Cheaper in 2026

What Medicaid Coverage for Spironolactone Actually Looks Like

Most state Medicaid programs cover spironolactone because it is an old, inexpensive generic with no brand-name equivalent driving the price up. The practical question is not whether your state covers it, but under what conditions and at what tier.

Spironolactone has been FDA-approved since 1960 for hypertension, edema related to heart failure, nephrotic syndrome, and primary hyperaldosteronism. Because those are well-established, on-label indications, they almost never trigger prior authorization (PA) on Medicaid. The friction shows up when your prescriber writes for an off-label use: hormonal acne, PCOS-related hirsutism, female pattern hair loss, or gender-affirming care.

How Medicaid Tiers Work for Generic Drugs

Medicaid formularies are organized differently from commercial insurance. Most states use a Preferred Drug List (PDL) rather than a strict numbered tier system. A drug that lands on the PDL is reimbursed without extra steps. One that is non-preferred may still be covered but requires your prescriber to justify why the preferred alternative does not work for you.

Because spironolactone is the only aldosterone antagonist in its class at this price point, states almost universally place it on the PDL. A 2023 Medicaid PDL analysis from the Kaiser Family Foundation found that generic aldosterone antagonists were preferred on the formulary in all 50 state Medicaid programs surveyed. That is encouraging. Still, the approved diagnosis on your claim matters.

State-by-State Snapshot: What to Expect

Medicaid programs change frequently. The table below reflects publicly posted PDLs and PA criteria as of early 2026. Always verify with your state Medicaid plan before you fill.

| State | Spiro on PDL? | PA for PCOS/acne? | Typical copay | |---|---|---|---| | California (Medi-Cal) | Yes | No for acne; sometimes for hair loss | $0 (most beneficiaries) | | Texas (STAR/CHIP) | Yes | Yes for off-label uses | $1 to $4 | | New York (Medicaid) | Yes | No for most female diagnoses | $0 to $3 | | Florida (Managed Medicaid) | Yes | Varies by managed care plan | $1 to $3 | | Illinois | Yes | No | $0 to $2 | | Ohio | Yes | Sometimes for PCOS | $1 to $3 | | Georgia | Yes | Yes for acne | $1 to $4 | | Washington | Yes | No | $0 to $2 | | Michigan | Yes | No for PCOS/acne | $0 to $3 | | Arizona (AHCCCS) | Yes | No | $0 to $2 |

If your state is not listed here, the practical starting point is to call the member services number on the back of your Medicaid card and ask: "Is spironolactone on the preferred drug list, and does it require prior authorization for [your diagnosis]?"

Who Needs Spironolactone: Women-Specific Indications

Spironolactone is prescribed to women for a wider range of conditions than it is to men. That asymmetry matters when you are filing a Medicaid claim, because the diagnosis code your provider enters can be the difference between a $0 copay and a denial.

PCOS and Hormonal Acne

Polycystic ovary syndrome affects roughly 8 to 13 percent of women of reproductive age worldwide, making it one of the most common endocrine conditions your prescriber will cite. Spironolactone blocks androgen receptors, so it reduces sebum production, hirsutism, and hormonal acne. The American Academy of Dermatology recognizes spironolactone as a first-line oral agent for hormonal acne in adult women, and ACOG acknowledges its use for hyperandrogenism in PCOS.

When your provider codes the visit as PCOS (ICD-10 E28.2), most state Medicaid programs process the claim without PA. If the visit is coded as acne vulgaris (L70.0) alone, some states flag it for PA review.

Female Pattern Hair Loss (Androgenetic Alopecia)

Spironolactone at doses of 100 to 200 mg per day is used off-label for female pattern hair loss (FPHL). A 2020 retrospective study in JAMA Dermatology of 1,000 women with FPHL found a clinician-reported response rate of approximately 74 percent at 12 months. This is the most common scenario where Medicaid PA gets triggered, because FPHL is considered a cosmetic condition by some states. Ask your provider to document functional or psychological impact in the PA letter.

Perimenopause and Menopause: Edema and Blood Pressure

During perimenopause, falling estrogen alters aldosterone sensitivity and renin-angiotensin-system dynamics, which can worsen fluid retention and blood pressure variability. Spironolactone's on-label hypertension indication means that postmenopausal women prescribed it for blood pressure face zero PA friction under Medicaid. If your provider is addressing both blood pressure and androgen-related symptoms, the hypertension diagnosis code alone may be sufficient to avoid PA for the full prescription.

Gender-Affirming Care

For transgender women and nonbinary individuals assigned male at birth, spironolactone is a common antiandrogen. Coverage varies significantly. California, Oregon, Washington, Illinois, and New York Medicaid programs explicitly cover gender-affirming medications without additional PA. Several southern states do not. The World Professional Association for Transgender Health (WPATH) Standards of Care 8 are increasingly referenced in Medicaid coverage determinations, but the legal field is actively shifting in 2026.

Pregnancy, Lactation, and Contraception: Required Reading

Spironolactone is contraindicated in pregnancy. This is not a precautionary soft warning. Animal studies show it causes feminization of male fetuses at doses used clinically in humans, and the FDA labels it Pregnancy Category C (old system) with specific fetal-risk language. Because the drug blocks androgen receptors, a female fetus exposed in utero may also be affected.

What This Means for You at Each Life Stage

Reproductive years (not trying to conceive): Every prescriber writing spironolactone for a woman of reproductive potential should discuss contraception at the same visit. ACOG recommends at least one reliable contraceptive method when spironolactone is used long-term. Combined oral contraceptives are a practical choice because they also treat the hormonal acne or PCOS you may be taking spironolactone for. Under Medicaid, contraception is covered at $0 cost-sharing under the ACA preventive-services mandate in most states.

Trying to conceive: Stop spironolactone before attempting pregnancy. The drug clears the body quickly, with a half-life of approximately 1.4 hours for spironolactone and 13 to 24 hours for its active metabolite canrenone, so a 1-to-2-cycle washout is standard clinical practice. Discuss timing with your provider.

Pregnancy: Do not take spironolactone. If you discover you are pregnant while on spironolactone, stop immediately and contact your OB or midwife. A single inadvertent early-pregnancy exposure does not automatically require termination, but you should discuss risk with a maternal-fetal medicine specialist.

Postpartum and lactation: Spironolactone transfers into breast milk. A small pharmacokinetic study (n=6) published in Clinical Pharmacology and Therapeutics measured canrenone levels in breast milk and estimated infant exposure at roughly 0.2 percent of the maternal dose. The clinical significance is unknown. Most lactation specialists consider low-dose spironolactone (25 to 50 mg) a possible option when the benefit to the mother is clear, but data are thin. LactMed lists it as "probably compatible" at low doses. Discuss with your provider and a lactation consultant before restarting postpartum.

Perimenopause and postmenopause: No pregnancy risk, so the contraception conversation drops away. Women in this life stage often tolerate spironolactone well. Watch potassium: kidneys become slightly less efficient with age, and hyperkalemia risk rises modestly. Your provider may check a basic metabolic panel more frequently, especially if you are also on an ACE inhibitor or ARB for blood pressure.

How to Get Spironolactone Cheaper: Every Option Mapped

Generic spironolactone is already inexpensive by drug-pricing standards, but "inexpensive" is relative when a Medicaid gap, a prior-authorization denial, or an insurance lapse puts you on cash pay.

Manufacturer Coupons and Patient Assistance

Because spironolactone is a generic with many manufacturers (including Accord, Aurobindo, Teva, and Sandoz), there is no single brand-sponsored copay card. Patient assistance programs (PAPs) from brand manufacturers do not apply here. Your discount options come from a different set of tools.

GoodRx, RxSaver, and Discount Cards

GoodRx and similar platforms negotiate cash prices at the pharmacy counter. As of early 2026, 25 mg spironolactone, 30 tablets, runs approximately $10 to $18 at major chains with a GoodRx coupon. The 100 mg strength runs roughly $12 to $22 for 30 tablets. These prices often beat a Medicaid copay of $4, meaning you can sometimes pay less at the counter with a coupon than through insurance, especially if your plan charges a dispensing fee per fill.

You cannot use a GoodRx coupon and your Medicaid card on the same fill at the same pharmacy. Pick the cheaper option per fill.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) lists spironolactone 25 mg at approximately $3.20 for 30 tablets and 100 mg at approximately $4.70 for 30 tablets as of 2026, plus a $5 pharmacist fee and $5 shipping per order. That is a potential total of about $14 for a 30-day supply of 100 mg with no membership required. Medicaid does not pay the Cost Plus Drugs invoices directly, but if you are in a coverage gap or your plan denies a fill, this is a concrete fallback.

HSA and FSA: Yes, Spironolactone Qualifies

Spironolactone purchased with a valid prescription is an eligible medical expense under IRS Publication 502, meaning you can pay with your Health Savings Account (HSA) or Flexible Spending Account (FSA) card at the pharmacy counter. This applies whether you buy through insurance or cash pay. HSA funds are triple-tax-advantaged, so if you are on a high-deductible health plan and paying out of pocket during your deductible phase, paying via HSA is always smarter than paying after-tax dollars.

FSA funds have a use-it-or-lose-it structure with a December 31 deadline in most plans (some allow a 2.5-month grace period or up to $640 rollover in 2026). If you have FSA funds expiring, stocking up on a 90-day supply of spironolactone is a legitimate use.

NeedyMeds and State Pharmaceutical Assistance Programs

NeedyMeds (needymeds.org) maintains a free database of state pharmaceutical assistance programs (SPAPs), disease-specific programs, and free clinic networks. Several states, including New Jersey (Pharmaceutical Assistance to the Aged and Disabled), Pennsylvania (PACE), and New York (EPIC), run SPAPs that supplement Medicaid or fill in for people just above Medicaid income limits. Search your state on NeedyMeds to see if you qualify.

340B Program Pharmacies

If you receive care at a federally qualified health center (FQHC), a community health center, or a 340B-covered hospital outpatient department, you may be able to fill spironolactone at 340B pricing, which can be lower than both Medicaid and GoodRx. Ask your clinic's pharmacy team whether they participate in 340B and whether you are eligible.

Prior Authorization: How to Fight a Denial

Getting a PA denial for spironolactone, especially for a clearly female condition like PCOS or hormonal acne, is frustrating but not final. Here is a practical framework for appealing.

Step 1: Get the Denial in Writing

Ask your pharmacy or your prescriber's office for the Explanation of Benefits (EOB) or the PA denial letter. The letter must state the specific reason for denial. Common reasons include: "not a covered indication," "step therapy required," or "formulary exclusion."

Step 2: Identify the Required Step Therapy Drug

Many Medicaid PA criteria for hormonal acne require a trial of a topical retinoid and a topical antibiotic before spironolactone is approved. If you have already tried those, your prescriber can document the failure. If the denial cites step therapy and you have not tried the alternatives, ask whether starting them simultaneously with spironolactone is medically appropriate.

Step 3: Use the Medical Necessity Letter Template

Your prescriber should submit a letter citing:

• Your specific ICD-10 code and clinical justification
• Relevant guideline support (for example, ACOG Practice Bulletin 194 on PCOS or the American Academy of Dermatology guidelines for acne in women)
• Why a preferred alternative is not appropriate (for example, combined oral contraceptives are contraindicated due to migraine with aura, or metformin was ineffective)

Step 4: Request an Expedited Appeal if Needed

If you have an acute clinical need, such as rapidly progressing hair loss or severe cystic acne affecting work or mental health, you can request an expedited appeal. Medicaid managed care plans are required to decide expedited appeals within 72 hours under federal regulations at 42 CFR 438.408.

Who This Drug Is Right For (and Who Should Think Twice)

Spironolactone is a good fit for:

• Women with PCOS, hormonal acne, or female pattern hair loss who have not responded to topical treatments
• Perimenopausal and postmenopausal women with hypertension, especially those who also have edema or who have not tolerated ACE inhibitors
• Women who need an aldosterone antagonist after a heart failure diagnosis
• Women using Medicaid or paying cash who want an effective, inexpensive option for androgen-related skin and hair concerns

Spironolactone is not appropriate for:

• Women who are pregnant or actively trying to conceive without a washout plan
• Women with hyperkalemia or significant kidney impairment (estimated GFR <30 mL/min per 1.73 m squared)
• Women taking high-dose potassium supplements or potassium-sparing diuretics without close lab monitoring
• Women who cannot commit to reliable contraception during reproductive years, because the fetal risk is real and not theoretical

Spironolactone Dosing by Condition: A Reference

Doses vary by indication, and sex-specific dosing data exist for some uses.

| Indication | Typical dose (women) | Notes | |---|---|---| | Hypertension | 25 to 100 mg once daily | Start low in perimenopausal women; monitor electrolytes | | Heart failure (HFrEF) | 25 to 50 mg once daily | Per the RALES trial (NEJM 1999), 25 mg reduced mortality by 30 percent in class III-IV HF | | PCOS, hirsutism | 50 to 200 mg daily | Many clinicians start at 50 mg and titrate up; 100 mg is most commonly studied | | Hormonal acne | 25 to 200 mg daily | A 2023 RCT in the BMJ showed 100 mg superior to placebo for facial acne in adult women | | Female pattern hair loss | 100 to 200 mg daily | Off-label; JAMA Dermatology 2020 study supports efficacy | | Primary aldosteronism | 100 to 400 mg daily | On-label; PA unlikely |

The RALES trial enrolled both men and women, though the majority were men, a known evidence gap. A 2020 subgroup analysis in the European Heart Journal suggested women with heart failure may derive at least equivalent benefit, though the sample size in that analysis was small.

The Evidence Gap: What We Know and What We Are Extrapolating

Women have been systematically underrepresented in cardiovascular and endocrine drug trials. Spironolactone is no exception.

The RALES trial, which established survival benefit in heart failure, was 55 percent male. Pharmacokinetic studies from the 1970s and 1980s that set standard dosing were conducted predominantly in men. The active metabolite canrenone has a longer half-life in women than in men in some, though not all, small studies, which could mean slightly higher steady-state drug exposure at the same mg/kg dose. That finding has not been confirmed in a large prospective trial.

For the PCOS, acne, and hair loss indications, women are obviously the study population, and those data are more directly applicable to you. The 2023 BMJ RCT on spironolactone for acne enrolled adult women exclusively and is the highest-quality trial available for that use.

Be honest with your prescriber about your full medication list. Spironolactone can interact with NSAIDs (reduces diuretic effect), ACE inhibitors and ARBs (hyperkalemia risk), lithium (increased lithium levels), and digoxin. Women are more likely than men to be on thyroid medications and antidepressants; neither class has a clinically significant interaction with spironolactone at standard doses, but your pharmacist should review the full list.